A Look At PACS Group (PACS) Valuation After Mixed Returns And Conflicting Fair Value Estimates

Why PACS Group Stock Is Drawing Investor Attention Now

PACS Group (PACS) has been catching investor interest after recent share price moves. The stock closed at US$35.43 and has shown mixed returns over the past week, month, and past 3 months.

See our latest analysis for PACS Group.

The recent 1 month share price return of 8.65% contrasts with a year to date share price return of a 10.33% decline, while the 1 year total shareholder return of 269.06% suggests earlier gains still weigh heavily in the longer term picture.

If PACS Group has you thinking more broadly about healthcare, it could be a good moment to widen your watchlist with 33 healthcare AI stocks

With PACS Group trading at US$35.43 and sitting below an analyst price target of about US$45.83 as well as an estimated intrinsic value gap, you might wonder whether this is a genuine value opportunity or whether the market is already pricing in future growth.

Most Popular Narrative: 1.2% Overvalued

The most followed narrative values PACS Group at about $35 per share, which sits slightly below the last close of $35.43 and points to a fairly tight valuation gap.

Rising demand for post-acute and long-term care from an aging U.S. population, combined with PACS Group's expanding footprint of over 35,000 beds, creates room for continued top line growth as occupancy and patient volumes increase, supporting higher revenue and earnings.

Read the complete narrative.

Curious what sits behind that projected uplift in revenue, margins and earnings per share. The narrative leans on detailed growth assumptions and a compression in the future P/E that is very different to today's multiple. The step change in profitability and scale is central to how this fair value was built.

Result: Fair Value of $35 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the rapid addition of over 100 facilities, along with the ongoing reliance on Medicaid reimbursement in key states, could easily disrupt those earnings and margin assumptions.

Find out about the key risks to this PACS Group narrative.

Another Lens: DCF Points To A Very Different Price

While the popular narrative sees PACS Group as about 1.2% overvalued at $35 per share, our DCF model presents a different view, with an estimated fair value of $75.64, or around 53.2% above the current $35.43 share price. Which perspective aligns with the level of risk you are willing to take?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out PACS Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 56 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of upside potential and possible risks feels finely balanced, this may be an appropriate time to explore the details yourself and decide where you stand, starting with 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If PACS Group is just one of several companies on your radar, this is a good moment to widen your opportunity set with a few focused stock lists.

• Target potential mispricing by scanning companies that combine earnings strength with appealing valuations using the 56 high quality undervalued stocks.
• Build a sturdier core for your portfolio by zeroing in on businesses highlighted in the solid balance sheet and fundamentals stocks screener (42 results).
• Get ahead of the market by reviewing the screener containing 24 high quality undiscovered gems before others start paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com